Related Experiment Video
Updated: Apr 28, 2026
Transuterine Fetal Tracheal Occlusion Model in Mice
Published on: February 5, 2021
Medical and regenerative solutions for congenital diaphragmatic hernia: a perinatal perspective
Jan Deprest1, Leonardo Gucciardo1, Patrice Eastwood1
1Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Insights
Congenital diaphragmatic hernia (CDH) has high mortality. Novel cell therapies using amniotic fluid stem cells offer a less invasive, more effective treatment approach for infants with CDH.
Area of Science:
- Regenerative Medicine
- Fetal Surgery
- Pediatric Surgery
Background:
- Congenital diaphragmatic hernia (CDH) affects 2,100 babies annually in the EU-27, with a 30% mortality rate.
- Current fetal surgery for severe CDH offers limited survival rates (50-60%) due to lung hypoplasia, pulmonary hypertension, and prematurity.
- Existing surgical repair methods using patches for large defects lead to recurrence and chest deformation.
Purpose of the Study:
- To explore alternative, less invasive, and more potent medical therapies for congenital diaphragmatic hernia.
- To investigate the potential of novel scaffolds or engineered constructs for functional postnatal repair.
- To evaluate autologous amniotic fluid-derived stem cells as a promising therapeutic strategy for CDH.
Main Methods:
- Review of current treatment limitations for congenital diaphragmatic hernia.
- Exploration of advanced therapeutic modalities including pharmacologic and cell therapy.
- Consideration of prenatal stem cell harvesting and noninvasive imaging for patient selection.
Main Results:
- Current treatments for CDH have significant limitations, including high failure rates and suboptimal repair outcomes.
- Novel strategies involving cell therapy and advanced biomaterials are needed to improve CDH treatment.
- Autologous amniotic fluid-derived stem cells present a potential solution for improved CDH management.
Conclusions:
- There is a critical need for advanced therapeutic strategies beyond current surgical interventions for congenital diaphragmatic hernia.
- Autologous amniotic fluid-derived stem cells hold significant promise for developing more effective and less invasive treatments for CDH.
- Prenatal harvesting of stem cells, guided by noninvasive imaging, could revolutionize CDH therapy.
Abstract:
In the EU-27, 2,100 babies with congenital diaphragmatic hernia (CDH) are born annually. CDH is fatal in 30% of them. Experimental fetal surgery in severe cases results in a survival rate of 50 to 60% at its best. Failure is due to insufficient lung growth, persistent pulmonary hypertension or prematurity induced by the procedure. For nonsurvivors alternative strategies are required. Survivors undergo anatomical repair, but large diaphragmatic defects are closed using a patch. At present the used materials are less than ideal, mainly because of recurrence and chest deformation. To overcome the above limitations, alternative medical therapies (pharmacologic or cell therapy) that are more potent and less invasive are needed. Also a more functional postnatal repair may be possible when using novel scaffolds or engineered constructs. We see a prominent place for autologous amniotic fluid-derived stem cells for these novel strategies, which could be prenatally harvested following appropriate patient selection by noninvasive imaging.
